Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430990 | 0.74 | — | — | |
| SCHEMBL21176808 | 0.69 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL29194337 | 0.69 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL23420282 | 0.67 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| Trimethylammonium SCHEMBL29815095 | 0.61 | — | — | |
| SCHEMBL16858635 | 0.60 | — | — | |
| Acetone SCHEMBL30150800 | 0.60 | — | — | |
| Trimethylammonium SCHEMBL28073004 | 0.58 | — | — | |
| Trimethylammonium SCHEMBL1247324 | 0.58 | — | — | |
| Acetic Acid SCHEMBL4254871 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552774-B2 | Method for preparing pyrotinib | SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD (CN) | 2026-02-17 | — | — | US | claimed |
| EP-4662222-A1 | PROCESS FOR THE PREPARATION OF TETRAPEPTIDE FRAGMENT OF LIRAGLUTIDE | Fresenius Kabi Oncology Ltd (IN) | 2025-12-17 | — | — | EP | claimed |
| EP-4615902-A1 | IDEAL STRUCTURE AND SCALABLE FABRICATION METHODS | The Regents of the University of California (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2025103334-A1 | PREPARATION METHOD AND USE OF DOTINURAD | 广东东阳光药业股份有限公司 | 2025-05-22 | — | — | WO | claimed |
| WO-2025094036-A1 | A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | PIRAMAL PHARMA LIMITED (IN) | 2025-05-08 | — | — | WO | claimed |
| US-20240368447-A1 | REUSABLE ENVIRONMENTALLY FRIENDLY FOOD COOLING TECHNOLOGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-11-07 | — | — | US | claimed |
| WO-2024166022-A1 | PROCESS FOR THE PREPARATION OF TETRAPEPTIDE FRAGMENT OF LIRAGLUTIDE | FRESENIUS KABI ONCOLOGY LTD (IN) | 2024-08-15 | — | — | WO | claimed |
| WO-2024140934-A1 | PREPARATION METHOD FOR LINKER-DRUG CONJUGATE AND INTERMEDIATE THEREOF | 上海复旦张江生物医药股份有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024103225-A1 | CATIONIC POLYESTER, PREPARATION METHOD THEREFOR AND USE THEREOF | 林桂孜 | 2024-05-23 | — | — | WO | claimed |
| WO-2024102885-A1 | IDEAL STRUCTURE AND SCALABLE FABRICATION METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-16 | — | — | WO | claimed |
| US-11485739-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-11-01 | — | — | US | claimed |
| US-11479592-B2 | Erythropoietin-derived peptide, preparation method and use thereof | ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY (CN) | 2022-10-25 | — | — | US | claimed |
| CN-108289964-B | Novel linkers and their use for specific coupling of drugs and biomolecules | 杭州多禧生物科技有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-112656948-B | Immunotherapy nano-drug carrier and preparation method thereof, drug with carrier and preparation method of drug | 宁波大学 | 2022-06-14 | — | — | CN | claimed |
| CN-114605833-A | Flame-retardant heat-conducting silicone rubber material and preparation method thereof | 安徽大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114539110-A | HDAC inhibitor containing RAS/RAF protein interfering group and preparation method thereof | 东南大学 | 2022-05-27 | — | — | CN | claimed |
| CN-107337713-B | Antibacterial peptides and preparation method thereof | 上海医药工业研究院 | 2022-05-13 | — | — | CN | claimed |
| CN-114316266-A | Reduction-responsive prodrug for realizing deep delivery by targeting CAIX and transcytosis | 宁波大学 | 2022-04-12 | — | — | CN | claimed |
| CN-114262299-A | Anti-neuritic compound and preparation method and medical application thereof | 中国药科大学 | 2022-04-01 | — | — | CN | claimed |
| CN-114040778-A | Cell binding molecule-Tubulysin derivative conjugate and preparation method thereof | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479592-B2 | Erythropoietin-derived peptide, preparation method and use thereof | EPOR, VIP, EPAS1 | ALDH1A1 3552/4885TSHR 489/4885 |
| US-12552774-B2 | Method for preparing pyrotinib | TYK2, ALK, AURKA | ALDH1A1 3094/4885TSHR 2855/4885 |
| US-11485739-B2 | Compounds useful as inhibitors of ATR kinase | ATR, CHEK1, ATRIP | ALDH1A1 3668/4885TSHR 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.